At least six people have exhibited symptoms of cerebral venous sinus thrombosis within six and 13 days of receiving the vaccine, the CDC and FDA said. Johnson & Johnson will also delay the vaccine’s rollout in Europe.
At least six people have exhibited symptoms of cerebral venous sinus thrombosis within six and 13 days of receiving the vaccine, the CDC and FDA said. Johnson & Johnson will also delay the vaccine’s rollout in Europe.